Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 4/2010

01-04-2010 | Colorectal Cancer

TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer

Authors: Norikatsu Miyoshi, MD, Hideshi Ishii, MD, Koshi Mimori, MD, Fumiaki Tanaka, MD, Toshiki Hitora, MD, Mitsuyoshi Tei, MD, Mitsugu Sekimoto, MD, Yuichiro Doki, MD, PhD, Masaki Mori, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 4/2010

Login to get access

Abstract

Background

Transglutaminase 2 (TGM2) plays a role in cell growth and survival through the antiapoptosis signaling pathway.

Methods

We analyzed TGM2 gene expression in 91 paired cases of colorectal cancer (CRC) and noncancerous regions and seven CRC cell lines to demonstrate the importance of TGM2 expression for the prediction of prognosis of CRC. TGM2 expression was higher in CRC tissue than in corresponding normal tissue by real-time reverse transcriptase–polymerase chain reaction (P = .015).

Results

Patients in the high TGM2 expression group showed a poorer overall survival rate than those in the low expression group (P = .001), indicating that the increase in TGM2 expression was an independent prognostic factor. TGM2 was also expressed in the seven CRC cell lines. The in vitro proliferation assay showed that TGM2 expression is involved with tumor growth.

Conclusions

The present study suggests that TGM2 is useful as a predictive marker for patient prognosis and may be a novel therapeutic target for CRC.
Appendix
Available only for authorised users
Literature
1.
Kohno SI, Luo C, Nawa A, et al. Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus. Cancer Gene Ther. 2007;14:918–26.CrossRefPubMed
2.
3.
Lorand L, Graham RM. Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat Rev Mol Cell Biol. 2003;4:140–56.CrossRefPubMed
4.
Antonyak MA, Singh US, Lee DA, et al. Effects of tissue transglutaminase on retinoic acid–induced cellular differentiation and protection against apoptosis. J Biol Chem. 2001;276:33582–7.CrossRefPubMed
5.
Boehm JE, Singh U, Combs C, et al. Tissue transglutaminase protects against apoptosis by modifying the tumor suppressor protein p110 Rb. J Biol Chem. 2002;277:20127–30.CrossRefPubMed
6.
Antonyak MA, Miller AM, Jansen JM, et al. Augmentation of tissue transglutaminase expression and activation by epidermal growth factor inhibit doxorubicin-induced apoptosis in human breast cancer cells. J Biol Chem. 2004;279:41461–7.CrossRefPubMed
7.
Mangala LS, Mehta K. Tissue transglutaminase (TG2) in cancer biology. Prog Exp Tumor Res. 2005;38:125–38.CrossRefPubMed
8.
9.
Mann AP, Verma A, Sethi G, et al. Overexpression of tissue transglutaminase leads to constitutive activation of nuclear factor-kappaB in cancer cells: delineation of a novel pathway. Cancer Res. 2006;66:8788–95.CrossRefPubMed
10.
Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer. 1997;80:1803–4.
11.
Mimori K, Mori M, Shiraishi T, et al. Clinical significance of tissue inhibitor of metalloproteinase expression in gastric carcinoma. Br J Cancer. 1997;76:531–6.PubMed
12.
Mori M, Staniunas RJ, Barnard GF, et al. The significance of carbonic anhydrase expression in human colorectal cancer. Gastroenterology. 1993;105:820–6.PubMed
13.
Fesus L, Piacentini M. Transglutaminase 2: an enigmatic enzyme with diverse functions. Trends Biochem Sci. 2002;27:534–9.CrossRefPubMed
14.
Mehta K. High levels of transglutaminase expression in doxorubicin-resistant human breast carcinoma cells. Int J Cancer. 1994;58:400–6.CrossRefPubMed
15.
Chen JS, Konopleva M, Andreeff M, et al. Drug-resistant breast carcinoma (MCF-7) cells are paradoxically sensitive to apoptosis. J Cell Physiol. 2004;200:223–34.CrossRefPubMed
16.
Mehta K, Fok J, Miller FR, et al. Prognostic significance of tissue transglutaminase in drug resistant and metastatic breast cancer. Clin Cancer Res. 2004;10:8068–76.CrossRefPubMed
17.
Herman JF, Mangala LS, Mehta K. Implications of increased tissue transglutaminase (TG2) expression in drug-resistant breast cancer (MCF-7) cells. Oncogene. 2006;25:3049–58.CrossRefPubMed
18.
Sarang Z, Molnar P, Nemeth T, et al. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice. Hepatology. 2005;42:578–87.CrossRefPubMed
19.
Aeschlimann D, Paulsson M. Transglutaminases: protein cross-linking enzymes in tissues and body fluids. Thromb Haemost. 1994;71:402–15.PubMed
20.
Aeschlimann D, Koeller MK, Allen-Hoffmann BL, Mosher DF. Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes. Detection and identification of transglutaminase gene products based on reverse transcription–polymerase chain reaction with degenerate primers. J Biol Chem. 1998;273:3452–60.CrossRefPubMed
21.
Chen JS, Mehta K. Tissue transglutaminase: an enzyme with a split personality. Int J Biochem Cell Biol. 1999;31:817–36.CrossRefPubMed
22.
Greenberg CS, Birckbichler PJ, Rice RH. Transglutaminases: multifunctional cross-linking enzymes that stabilize tissues. FASEB J. 1991;5:3071–7.PubMed
23.
Ai L, Kim WJ, Demircan B, et al. The transglutaminase 2 gene (TGM2.), a potential molecular marker for chemotherapeutic drug sensitivity, is epigenetically silenced in breast cancer. Carcinogenesis. 2008;29:510–8.CrossRefPubMed
24.
Andre T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;25:3732–8.CrossRefPubMed
25.
Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296–10.CrossRefPubMed
26.
Kornmann M, Formentini A, Ette C, et al. Prognostic factors influencing the survival of patients with colon cancer receiving adjuvant 5-FU treatment. Eur J Surg Oncol. 2008;34:1316–21.PubMed
27.
Bathe OF, Dowden S, Sutherland F, et al. 2004 Phase II study of neoadjuvant 5-FU + leucovorin + CPT-11 in patients with resectable liver metastases from colorectal adenocarcinoma. BMC Cancer. 4:32.CrossRefPubMed
28.
Lacy AM, Garcia-Valdecasas JC, Delgado S, et al. Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial. Lancet. 2002;359:2224–9.CrossRefPubMed
29.
Weeks JC, Nelson H, Gelber S, et al. Short-term quality-of-life outcomes following laparoscopic-assisted colectomy vs open colectomy for colon cancer: a randomized trial. JAMA. 2002;287:321–8.CrossRefPubMed
30.
Group COoSTS. 2004 A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 350:2050–9.CrossRef
31.
Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007;25:3061–8.CrossRefPubMed
32.
Han JA, Park SC. Reduction of transglutaminase 2 expression is associated with an induction of drug sensitivity in the PC-14 human lung cancer cell line. J Cancer Res Clin Oncol. 1999;125:89–95.CrossRefPubMed
33.
Devarajan E, Chen J, Multani AS, et al. Human breast cancer MCF-7 cell line contains inherently drug-resistant subclones with distinct genotypic and phenotypic features. Int J Oncol. 2002;20:913–20.PubMed
Metadata
Title
TGM2 Is a Novel Marker for Prognosis and Therapeutic Target in Colorectal Cancer
Authors
Norikatsu Miyoshi, MD
Hideshi Ishii, MD
Koshi Mimori, MD
Fumiaki Tanaka, MD
Toshiki Hitora, MD
Mitsuyoshi Tei, MD
Mitsugu Sekimoto, MD
Yuichiro Doki, MD, PhD
Masaki Mori, MD, PhD, FACS
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 4/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-009-0865-y

Other articles of this Issue 4/2010

Annals of Surgical Oncology 4/2010 Go to the issue

Head and Neck Oncology

Long-Term Single-Center Results of Management of Ethmoid Adenocarcinoma: 95 Patients over 28 Years

Pancreatic Tumors

Challenges in the Study of Adjuvant Chemoradiation After Pancreaticoduodenectomy

Hepatobiliary Tumors

Predictors of Survival in Periampullary Cancers Following Pancreaticoduodenectomy

Thoracic Oncology

Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer

Translational Research and Biomarkers

Rate of Freeze Alters the Immunologic Response After Cryoablation of Breast Cancer

Gynecologic Oncology

Microscopic Evaluation of Lymph-Node-Bearing Tissue in Early-Stage Cervical Cancer: A Dual-Institution Review